The health effects of non-prescribed anabolic–androgenic steroid use: Findings from The Performance and image-enhancing drugs UseRS' Health (PUSH) audit

IF 3 3区 医学 Q2 SUBSTANCE ABUSE Drug and alcohol review Pub Date : 2024-07-07 DOI:10.1111/dar.13899
Matthew Dunn, Joshua Dawe, Beng Eu, Kevin Lee, Timothy Piatkowski, Mark Stoové
{"title":"The health effects of non-prescribed anabolic–androgenic steroid use: Findings from The Performance and image-enhancing drugs UseRS' Health (PUSH) audit","authors":"Matthew Dunn,&nbsp;Joshua Dawe,&nbsp;Beng Eu,&nbsp;Kevin Lee,&nbsp;Timothy Piatkowski,&nbsp;Mark Stoové","doi":"10.1111/dar.13899","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>To ascertain the adverse health outcomes experienced by those using prescribed testosterone and non-prescribed anabolic–androgenic steroids presenting to general practitioner (GP) clinics.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Retrospective clinical audit from nine GP clinics in major metropolitan areas across three Australian states. Data included demographic and individual characteristics (age, sexuality, body mass index, smoking status and HIV status); performance and image-enhancing drug use (type, reasons for use, patient-reported adverse effects); and blood biochemistry measurements (lipid profiles, liver function tests and red blood cell tests). Adverse health outcomes included evidence of polycythaemia, hypertension, liver abnormalities and hypercholesterolemia.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Three hundred men were identified as either using prescribed testosterone (66%; <i>n</i> = 197) or non-prescribed anabolic–androgenic steroids (AAS) (34%; <i>n</i> = 103). Individuals in the prescribed group were more likely to be older (<i>p</i> &lt; 0.001), gay or bisexual (<i>p</i> &lt; 0.001) and living with diagnosed HIV (<i>p</i> &lt; 0.001) compared to individuals in the non-prescribed group. Abnormal liver function, polycythemia and gynecomastia were the top three adverse events experienced. When adjusting for age, sexuality, HIV status and smoking status, those who used non-prescribed AAS were more likely to experience any adverse event (aPR = 1.28; 95% CI 1.01–1.60; <i>p</i> = 0.038), hypertension (aPR = 1.86; 95% CI 1.19–2.91; <i>p</i> = 0.006) and liver abnormalities (aPR = 1.51; 95% CI 1.04–2.20; <i>p</i> = 0.030) compared to those using prescribed testosterone.</p>\n </section>\n \n <section>\n \n <h3> Discussion and Conclusion</h3>\n \n <p>For GPs who have clients who may be using, or who they suspect of using, AAS, these findings highlight the importance of not only exploring a patient's history of the adverse effects they have experienced, but that measuring for these other conditions may provide a more accurate clinical picture.</p>\n </section>\n </div>","PeriodicalId":11318,"journal":{"name":"Drug and alcohol review","volume":"43 7","pages":"1967-1975"},"PeriodicalIF":3.0000,"publicationDate":"2024-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dar.13899","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and alcohol review","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dar.13899","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

To ascertain the adverse health outcomes experienced by those using prescribed testosterone and non-prescribed anabolic–androgenic steroids presenting to general practitioner (GP) clinics.

Methods

Retrospective clinical audit from nine GP clinics in major metropolitan areas across three Australian states. Data included demographic and individual characteristics (age, sexuality, body mass index, smoking status and HIV status); performance and image-enhancing drug use (type, reasons for use, patient-reported adverse effects); and blood biochemistry measurements (lipid profiles, liver function tests and red blood cell tests). Adverse health outcomes included evidence of polycythaemia, hypertension, liver abnormalities and hypercholesterolemia.

Results

Three hundred men were identified as either using prescribed testosterone (66%; n = 197) or non-prescribed anabolic–androgenic steroids (AAS) (34%; n = 103). Individuals in the prescribed group were more likely to be older (p < 0.001), gay or bisexual (p < 0.001) and living with diagnosed HIV (p < 0.001) compared to individuals in the non-prescribed group. Abnormal liver function, polycythemia and gynecomastia were the top three adverse events experienced. When adjusting for age, sexuality, HIV status and smoking status, those who used non-prescribed AAS were more likely to experience any adverse event (aPR = 1.28; 95% CI 1.01–1.60; p = 0.038), hypertension (aPR = 1.86; 95% CI 1.19–2.91; p = 0.006) and liver abnormalities (aPR = 1.51; 95% CI 1.04–2.20; p = 0.030) compared to those using prescribed testosterone.

Discussion and Conclusion

For GPs who have clients who may be using, or who they suspect of using, AAS, these findings highlight the importance of not only exploring a patient's history of the adverse effects they have experienced, but that measuring for these other conditions may provide a more accurate clinical picture.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
非处方合成代谢雄性类固醇使用对健康的影响:性能和图像增强药物使用者健康(PUSH)审计结果。
简介:目的目的:确定在全科医生(GP)诊所就诊的使用处方睾酮和非处方合成代谢雄性类固醇的患者的不良健康后果:方法:对澳大利亚三个州主要都市地区的九家全科医生诊所进行回顾性临床审计。数据包括人口统计学特征和个人特征(年龄、性取向、体重指数、吸烟状况和 HIV 感染状况);使用性能和图像增强药物的情况(类型、使用原因、患者报告的不良反应);以及血液生化测量(血脂概况、肝功能检测和红细胞检测)。不良健康后果包括多发性红细胞血症、高血压、肝功能异常和高胆固醇血症:三百名男性被确定为使用处方睾酮(66%;n = 197)或非处方合成代谢雄性类固醇(AAS)(34%;n = 103)。处方组中的个体年龄更大(P 讨论和结论:对于那些可能正在使用或怀疑正在使用合成代谢雄性类固醇的客户的全科医生来说,这些研究结果强调了不仅要了解患者的不良反应史,而且要对这些其他情况进行测量,这样才能提供更准确的临床信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug and alcohol review
Drug and alcohol review SUBSTANCE ABUSE-
CiteScore
4.80
自引率
10.50%
发文量
151
期刊介绍: Drug and Alcohol Review is an international meeting ground for the views, expertise and experience of all those involved in studying alcohol, tobacco and drug problems. Contributors to the Journal examine and report on alcohol and drug use from a wide range of clinical, biomedical, epidemiological, psychological and sociological perspectives. Drug and Alcohol Review particularly encourages the submission of papers which have a harm reduction perspective. However, all philosophies will find a place in the Journal: the principal criterion for publication of papers is their quality.
期刊最新文献
A chance for countries to support Ireland's world-leading cancer warning labels for alcohol containers. Drinking practices: The variation of drinking events across intersections of sex, age and household income. Childhood traumatic experiences and vaping among Australian adolescents: A prospective investigation. Issue Information Australian psychologists' attitudes towards psychedelic-assisted therapy and training following a world-first drug down-scheduling.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1